Why the study?
Do different antihypertensive therapies (amlodipine, bisoprolol/HCTZ, enalapril) differentially affect quality of life in hypertensive patients?
Do different antihypertensive therapies (amlodipine, bisoprolol/HCTZ, enalapril) differentially affect quality of life in hypertensive patients?
Changes in quality of life during antihypertensive therapy correlate directly with adverse events rather than the degree of blood pressure reduction.
Answers are grounded in this paper and cite their sources.
Adverse events should guide antihypertensive selection to preserve quality of life; extends RCT evidence that blood pressure reduction magnitude does not drive patient-reported outcomes.
Quality of life is an important attribute of antihypertensive therapy. Previous studies have not addressed the importance of a patient's prior pharmacotherapy on quality of life, which may serve as the basis of reference for a new therapy. Nor have previous studies compared commonly used quality of life instruments for consistency, or investigated whether improvement or worsening of quality of life correlates with adverse events or blood pressure reduction. Two hundred eighteen hypertensive patients with diastolic blood pressure (95 to 114 mm Hg) after a 4- to 5-week placebo washout period were enrolled in a randomized double-blind, parallel group dose-escalation trial to compare the effects of amlodipine (2.5 to 10 mg), bisoprolol (2.5 to 10 mg)/hydrochlorothiazide (HCTZ) 6.25, and enalapril (5 to 20 mg) on blood pressure, adverse events, and quality of life. Three quality of life instruments (General Well-Being Index, Vital Signs Quality of Life, Zung Self-Rating Depression Scale) were administered during original therapy, after placebo washout, and after 12 weeks of optimally titrated clinical trial pharmacotherapy. Our results demonstrated that removal from prior therapy had no detectable influence on subsequent evaluation of quality of life. The three quality of life instruments were consistent with the changes observed with the three therapies: a trend toward better quality of life with amlodipine and bisoprolol/HCTZ. Adverse events, but not systolic or diastolic blood pressure reduction correlated directly with changes in quality of life.
No takes yet. Share an insight, caveat, or question.
A 1996 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: